Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Serapha Bio
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Serapha Bio is a privately held clinical-stage biotechnology company developing in vivo base editing therapies for Alpha-1 Antitrypsin Deficiency. The company emerged publicly on June 23, 2026 alongside an announced reverse merger with Boundless Bio and a concurrent $230 million financing. Its lead program, SERP-01, is designed to correct the SERPINA1 E342K (PiZZ) mutation, the most common severe genetic cause of AATD. SERP-01 was licensed in June 2026 from YolTech Therapeutics, where it had been developed as YOLT-202 for Greater China. Serapha is positioning the asset as a potentially best-in-class, one-time genetic medicine for liver and lung disease associated with AATD.
- Therapeutic areas
- Rare Diseases
- Modalities
- Gene therapyCRISPR-based therapy
- Industry
- Biotech
02
Partnerships
YolTech TherapeuticsBoundless Bio
Beyond the preview
Go deeper on Serapha Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serapha Bio.